Literature DB >> 12378021

Higher prevalence of peripheral arthritis among ankylosing spondylitis patients.

Ji-Hyun Lee1, Jae-Bum Jun, Sungsoo Jung, Sang-Cheol Bae, Dae-Hyun Yoo, Think-You Kim, Seong Yoon Kim, Tae-Hwan Kim.   

Abstract

This study was performed to define the clinical spectrum and disease manifestations of ankylosing spondylitis (AS) in a referral hospital setting. We identified the differences in clinical manifestations according to the sex, the age at onset, the presence of peripheral arthritis and the presence of HLA B27. A total 412 patients (357 males, 55 females) were recruited. Eighty-seven percent were men and 155 out of 412 patients (35%) were juvenile-onset. HLA B27 was detected in 385 patients (93%). Peripheral joint involvement was noted in 287 of total AS cases (juvenile- onset ankylosing spondylitis (JOAS), 82%; adult-onset ankylosing spondylitis (AOAS), 61%), and was more common than those reported in other studies. A greater portion of patients with JOAS had peripheral arthritis and peripheral enthesitis than the patients with AOAS. The patients with peripheral arthritis showed a younger age at onset and an increased tendency of having enthesitis and trauma history. The natural history of Korean AS appears largely similar to those seen in Europe and North America, except a few differences. JOAS was quite common and AS was about nine times more common in men than in women. In addition, the HLA B27 antigen frequency was 93%, which is higher than those reported in other studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12378021      PMCID: PMC3054932          DOI: 10.3346/jkms.2002.17.5.669

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  14 in total

1.  Infection and work stress are potential triggers of ankylosing spondylitis.

Authors:  Jane Zochling; Martin H J Bohl-Bühler; Xenofon Baraliakos; Ernst Feldtkeller; Jürgen Braun
Journal:  Clin Rheumatol       Date:  2006-04-22       Impact factor: 2.980

2.  Clinical and radiographic features of adult-onset ankylosing spondylitis in Korean patients: comparisons between males and females.

Authors:  Young-Ok Jung; Inje Kim; Suho Kim; Chang-Hee Suh; Han Jung Park; Won Park; Seoung Ryul Kwon; Jae Cheon Jeong; Yun Jong Lee; Hee Jung Ryu; Young Bae Park; Jisoo Lee; You-Hyun Lee; Young Il Seo; Won Tae Chung; Seung-Jae Hong; Yeon-Sik Hong; Han Joo Baek; Hyo Jin Choi; Hyo-Jong Kang; Chan-Hee Lee; Sang-Hyon Kim; Hyun Ah Kim
Journal:  J Korean Med Sci       Date:  2010-03-19       Impact factor: 2.153

3.  Ankylosing spondylitis and undifferentiated spondyloarthritis in Kuwait: a comparison between Arabs and South Asians.

Authors:  S S Uppal; Mini Abraham; R I Chowdhury; Rakesh Kumari; E M Pathan; A Al Rashed
Journal:  Clin Rheumatol       Date:  2005-10-21       Impact factor: 2.980

Review 4.  Ankylosing Spondylitis: HLA-B*27-Positive Versus HLA-B*27-Negative Disease.

Authors:  Nurullah Akkoç; Handan Yarkan; Gökçe Kenar; Muhammad A Khan
Journal:  Curr Rheumatol Rep       Date:  2017-05       Impact factor: 4.592

Review 5.  Expanding the armamentarium for the spondyloarthropathies.

Authors:  Paul M Peloso; Jürgen Braun
Journal:  Arthritis Res Ther       Date:  2004-06-21       Impact factor: 5.156

Review 6.  The dynamic evolution of rheumatology in Korea.

Authors:  Ho-Youn Kim; Yeong-Wook Song
Journal:  Nat Rev Rheumatol       Date:  2015-12-17       Impact factor: 20.543

7.  Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab.

Authors:  Sang-Hoon Lee; Won Park; Sung Won Lee; Hyun Ah Kim; Jung-Yoon Choe; Sang-Heon Lee; Shin-Seok Lee; Sung-Hwan Park; Min-Chan Park; Dong-Hyuk Sheen; Hye Soon Lee; Yeon-Ah Lee; Yusun Lee; Tae-Hwan Kim
Journal:  Int J Rheum Dis       Date:  2020-07-29       Impact factor: 2.454

Review 8.  Infliximab: 12 years of experience.

Authors:  Josef S Smolen; Paul Emery
Journal:  Arthritis Res Ther       Date:  2011-05-25       Impact factor: 5.156

9.  Safety and clinical responses in ankylosing spondylitis after three months of etanercept therapy.

Authors:  Chan-Bum Choi; Tae-Jong Kim; Hee-Jin Park; Wan-Sik Uhm; Jae-Bum Jun; Sang-Cheol Bae; Dae-Hyun Yoo; Tae-Hwan Kim
Journal:  J Korean Med Sci       Date:  2008-10       Impact factor: 2.153

Review 10.  Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis.

Authors:  Ofir Elalouf; Ori Elkayam
Journal:  Ther Clin Risk Manag       Date:  2015-11-19       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.